Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01729819 · ClinicalTrials.gov registry record · Phase 2
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT01729819 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 106 participants.
The verdict
NCT01729819, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of nocturnal voids during 3 months of treatment
Interventions
- DRUG Tolterodine tartrate extended release capsules
- DRUG Desmopressin orally disintegrating tablets
- DRUG Placebo orally disintegrating tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01729819
The ClinicalTrials.gov registry entry for NCT01729819 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tolterodine tartrate extended release capsules is the first listed.
NCT01729819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01729819 about?
NCT01729819 is a clinical study titled "Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women". The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of nocturnal voids during 3 months of treatment
What is the current status of trial NCT01729819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2013-01. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01729819?
The interventions under investigation include: Tolterodine tartrate extended release capsules (DRUG), Desmopressin orally disintegrating tablets (DRUG), Placebo orally disintegrating tablets (DRUG).
Who is sponsoring clinical trial NCT01729819?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.